Mark D. Hauge

Gemcitabine, Cisplatin, and Radiotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942

Michael G. Haddock, Revathi Swaminathan, Nathan R. Foster et al. · Journal of Clinical Oncology · 2007 · 69 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)

Elizabeth A. Johnson, Randolph S. Marks, Sumithra J. Mandrekar et al. · Lung Cancer · 2007 · 68 citations

Medicine, Oncology, Pharmacotherapy +10

Insufficiency Fractures of the Pelvis That Simulate Metastatic Disease

Mark D. Hauge, Kay L. Cooper, Scott C. Litin · Mayo Clinic Proceedings · 1988 · 40 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

Aminah Jatoi, Shaker R. Dakhil, Nathan R. Foster et al. · Journal of Thoracic Oncology · 2008 · 35 citations · Full text

Medicine, Oncology, Pharmacology +16

The HL-A system defined with lymphocytotoxic and platelet antibodies in relation to kidney transplantation.

F Kissmeyer-Nielsen, A Svejgaard, Mark D. Hauge · PubMed · 1969 · 13 citations

Medicine, Hematology, Immunology +11